KR20230022151A - 거대고리 화합물의 치료 용도 - Google Patents
거대고리 화합물의 치료 용도 Download PDFInfo
- Publication number
- KR20230022151A KR20230022151A KR1020227034099A KR20227034099A KR20230022151A KR 20230022151 A KR20230022151 A KR 20230022151A KR 1020227034099 A KR1020227034099 A KR 1020227034099A KR 20227034099 A KR20227034099 A KR 20227034099A KR 20230022151 A KR20230022151 A KR 20230022151A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- carcinoma
- compound
- met
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062984159P | 2020-03-02 | 2020-03-02 | |
| US62/984,159 | 2020-03-02 | ||
| PCT/US2021/020255 WO2021178296A1 (en) | 2020-03-02 | 2021-03-01 | Therapeutic uses of macrocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230022151A true KR20230022151A (ko) | 2023-02-14 |
Family
ID=77613771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227034099A Ceased KR20230022151A (ko) | 2020-03-02 | 2021-03-01 | 거대고리 화합물의 치료 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250262216A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4114530A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023515687A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230022151A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115397514A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021229457A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022017425A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174455A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295938A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022010945A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021178296A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111902417B (zh) | 2018-04-25 | 2023-07-28 | 北京普祺医药科技股份有限公司 | 一种二芳基巨环化合物、药物组合物以及其用途 |
| WO2022171139A1 (zh) * | 2021-02-10 | 2022-08-18 | 北京国鸿生物医药科技有限公司 | 一种巨环化合物、药物组合物以及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| WO2015112806A2 (en) * | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| BR112018000297A2 (pt) * | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
| AU2017302019A1 (en) * | 2016-07-28 | 2019-02-07 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| PT3658148T (pt) * | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Compostos macrocíclicos e utilizações dos mesmos |
| WO2021063276A1 (zh) * | 2019-09-30 | 2021-04-08 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
-
2021
- 2021-03-01 US US17/905,503 patent/US20250262216A1/en not_active Abandoned
- 2021-03-01 EP EP21764224.8A patent/EP4114530A4/en not_active Withdrawn
- 2021-03-01 CA CA3174455A patent/CA3174455A1/en active Pending
- 2021-03-01 JP JP2022552626A patent/JP2023515687A/ja active Pending
- 2021-03-01 AU AU2021229457A patent/AU2021229457A1/en not_active Abandoned
- 2021-03-01 MX MX2022010945A patent/MX2022010945A/es unknown
- 2021-03-01 KR KR1020227034099A patent/KR20230022151A/ko not_active Ceased
- 2021-03-01 WO PCT/US2021/020255 patent/WO2021178296A1/en not_active Ceased
- 2021-03-01 BR BR112022017425A patent/BR112022017425A2/pt not_active IP Right Cessation
- 2021-03-01 IL IL295938A patent/IL295938A/en unknown
- 2021-03-01 CN CN202180023879.XA patent/CN115397514A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL295938A (en) | 2022-10-01 |
| EP4114530A1 (en) | 2023-01-11 |
| WO2021178296A1 (en) | 2021-09-10 |
| JP2023515687A (ja) | 2023-04-13 |
| AU2021229457A1 (en) | 2022-10-20 |
| CA3174455A1 (en) | 2021-09-10 |
| US20250262216A1 (en) | 2025-08-21 |
| BR112022017425A2 (pt) | 2022-11-29 |
| EP4114530A4 (en) | 2024-04-17 |
| MX2022010945A (es) | 2022-10-07 |
| CN115397514A (zh) | 2022-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102772574B1 (ko) | 키랄 디아릴 매크로사이클 및 이것의 용도 | |
| JP7193475B2 (ja) | ジアリール大環状化合物を含む併用療法 | |
| Rizzolio et al. | CDK inhibitors: from the bench to clinical trials | |
| US20140088143A1 (en) | Method of Inhibiting Constitutively Active Phosphorylated FLT3 Kinase | |
| EP3585389A1 (en) | Treatment of egfr-driven cancer with fewer side effects | |
| AU2017417160A1 (en) | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha | |
| EP4065395A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| JP2006524634A (ja) | ミエローマ細胞の細胞増殖、移動もしくはアポトーシス、又は血管形成と関係する疾患の治療用の組み合わせ | |
| WO2019199883A1 (en) | Treatment of cancers having driving oncogenic mutations | |
| JP2022551652A (ja) | 線維芽細胞増殖因子受容体シグナル伝達の調節不全を伴う癌の標的処置 | |
| KR20240095536A (ko) | 헤테로방향족 매크로사이클릭 에테르 화합물을 사용한 고형 종양의 치료 방법 | |
| US10835525B2 (en) | Method of inhibiting mutant C-KIT | |
| JP2023515687A (ja) | 大環状化合物の治療使用 | |
| KR20240115884A (ko) | Fgfr 키나제 억제제를 이용하는 암의 치료 | |
| US20230241052A1 (en) | Method of inhibiting mutant c-kit | |
| EP4034121A1 (en) | Treatment of egfr mutant-related cancers using a combination of egfr and cdk4/6 inhibitors | |
| CN101010082A (zh) | 米哚妥林用于治疗胃肠道基质瘤的用途 | |
| CN121969398A (zh) | 抗体偶联药物及其用途 | |
| JP2023530734A (ja) | アイソフォーム特異的アルデヒドデヒドロゲナーゼ阻害剤 | |
| BR122024018560A2 (pt) | Uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin- 3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |